{
    "ticker": "PDEX",
    "name": "PaxMedica, Inc.",
    "description": "PaxMedica, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for the treatment of autism spectrum disorder (ASD) and other neurodevelopmental conditions. Founded in 2018, PaxMedica operates with a mission to provide novel treatment options that improve the quality of life for patients and their families. The company's lead product candidate, PAX-101, is a proprietary formulation of a well-known drug that has shown promising results in early clinical trials for treating symptoms associated with ASD. The company's unique approach combines established pharmacological principles with advanced clinical methodologies to explore new avenues in neurotherapeutics. With a strong emphasis on research and development, PaxMedica is committed to advancing the science of treating neurodevelopmental disorders and addressing the unmet medical needs of patients. The company\u2019s passion for innovation and dedication to patient care are at the forefront of its operations as it strives to make a significant impact in this challenging therapeutic area.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2018",
    "website": "https://www.paxmedica.com",
    "ceo": "Dr. T. Paul A. McCray",
    "social_media": {
        "twitter": "https://twitter.com/PaxMedicaInc",
        "linkedin": "https://www.linkedin.com/company/paxmedica/"
    },
    "investor_relations": "https://www.paxmedica.com/investors",
    "key_executives": [
        {
            "name": "Dr. T. Paul A. McCray",
            "position": "CEO"
        },
        {
            "name": "Dr. Patrick J. O'Shea",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PAX-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "PaxMedica, Inc. | Innovative Therapies for Autism Spectrum Disorder",
        "meta_description": "Explore PaxMedica, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for autism spectrum disorder and other neurodevelopmental conditions.",
        "keywords": [
            "PaxMedica",
            "Biopharmaceuticals",
            "Autism",
            "Neurodevelopmental Disorders",
            "PAX-101"
        ]
    },
    "faq": [
        {
            "question": "What is PaxMedica known for?",
            "answer": "PaxMedica is known for developing innovative therapies for autism spectrum disorder and other neurodevelopmental conditions."
        },
        {
            "question": "Who is the CEO of PaxMedica?",
            "answer": "Dr. T. Paul A. McCray is the CEO of PaxMedica, Inc."
        },
        {
            "question": "Where is PaxMedica headquartered?",
            "answer": "PaxMedica is headquartered in New York, New York, USA."
        },
        {
            "question": "What is PaxMedica's main product?",
            "answer": "PaxMedica's main product is PAX-101, a therapeutic candidate for autism spectrum disorder."
        },
        {
            "question": "When was PaxMedica founded?",
            "answer": "PaxMedica was founded in 2018."
        }
    ],
    "competitors": [
        "ACAD",
        "AVXL",
        "AXSM",
        "SAGE"
    ],
    "related_stocks": [
        "NVAX",
        "MRNA",
        "PFE",
        "BMY"
    ]
}